These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24351928)

  • 1. Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.
    Yang C; Swallows CL; Zhang C; Lu J; Xiao H; Brady RO; Zhuang Z
    Proc Natl Acad Sci U S A; 2014 Jan; 111(1):249-54. PubMed ID: 24351928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation.
    Yang C; Wang H; Zhu D; Hong CS; Dmitriev P; Zhang C; Li Y; Ikejiri B; Brady RO; Zhuang Z
    Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1137-42. PubMed ID: 25583479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones.
    Yang C; Rahimpour S; Lu J; Pacak K; Ikejiri B; Brady RO; Zhuang Z
    Proc Natl Acad Sci U S A; 2013 Jan; 110(3):966-71. PubMed ID: 23277556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of the proteostasis network of plant cells promotes the post-endoplasmic reticulum trafficking of recombinant mutant (L444P) human β-glucocerebrosidase.
    Babajani G; Kermode AR
    Plant Signal Behav; 2014; 9(3):e28714. PubMed ID: 24713615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease.
    Lu J; Yang C; Chen M; Ye DY; Lonser RR; Brady RO; Zhuang Z
    Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21200-5. PubMed ID: 22160715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase.
    Fog CK; Zago P; Malini E; Solanko LM; Peruzzo P; Bornaes C; Magnoni R; Mehmedbasic A; Petersen NHT; Bembi B; Aerts JFMG; Dardis A; Kirkegaard T
    EBioMedicine; 2018 Dec; 38():142-153. PubMed ID: 30497978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol.
    Sreeramulu S; Gande SL; Göbel M; Schwalbe H
    Angew Chem Int Ed Engl; 2009; 48(32):5853-5. PubMed ID: 19585625
    [No Abstract]   [Full Text] [Related]  

  • 8. Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease.
    Jian J; Tian QY; Hettinghouse A; Zhao S; Liu H; Wei J; Grunig G; Zhang W; Setchell KDR; Sun Y; Overkleeft HS; Chan GL; Liu CJ
    EBioMedicine; 2016 Nov; 13():212-224. PubMed ID: 27789271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant.
    Babajani G; Tropak MB; Mahuran DJ; Kermode AR
    Mol Genet Metab; 2012 Jul; 106(3):323-9. PubMed ID: 22592100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte.
    Ota A; Zhang J; Ping P; Han J; Wang Y
    Circ Res; 2010 Apr; 106(8):1404-12. PubMed ID: 20299663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl.
    Lu J; Chiang J; Iyer RR; Thompson E; Kaneski CR; Xu DS; Yang C; Chen M; Hodes RJ; Lonser RR; Brady RO; Zhuang Z
    Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21665-70. PubMed ID: 21098288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease.
    Li Z; Li T; Dai S; Xie X; Ma X; Zhao W; Zhang W; Li J; Wang PG
    Chembiochem; 2013 Jul; 14(10):1239-47. PubMed ID: 23775891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.
    Lieberman RL; Wustman BA; Huertas P; Powe AC; Pine CW; Khanna R; Schlossmacher MG; Ringe D; Petsko GA
    Nat Chem Biol; 2007 Feb; 3(2):101-7. PubMed ID: 17187079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase.
    Khanna R; Benjamin ER; Pellegrino L; Schilling A; Rigat BA; Soska R; Nafar H; Ranes BE; Feng J; Lun Y; Powe AC; Palling DJ; Wustman BA; Schiffmann R; Mahuran DJ; Lockhart DJ; Valenzano KJ
    FEBS J; 2010 Apr; 277(7):1618-38. PubMed ID: 20148966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells.
    Zhang T; Hamza A; Cao X; Wang B; Yu S; Zhan CG; Sun D
    Mol Cancer Ther; 2008 Jan; 7(1):162-70. PubMed ID: 18202019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease.
    Tan YL; Genereux JC; Pankow S; Aerts JM; Yates JR; Kelly JW
    Chem Biol; 2014 Aug; 21(8):967-76. PubMed ID: 25126989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chaperone-mediated hierarchical control in targeting misfolded proteins to aggresomes.
    Zhang X; Qian SB
    Mol Biol Cell; 2011 Sep; 22(18):3277-88. PubMed ID: 21775628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of the C-terminal domain of Harc for binding to Hsp70 and Hop as well as its response to heat shock.
    Cartledge K; Elsegood C; Roiniotis J; Hamilton JA; Scholz GM
    Biochemistry; 2007 Dec; 46(51):15144-52. PubMed ID: 18052042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
    Li N; Xu M; Wang B; Shi Z; Zhao Z; Tang Y; Wang X; Sun J; Chen L
    J Med Chem; 2019 Dec; 62(23):10798-10815. PubMed ID: 31725288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.
    Luan Z; Higaki K; Aguilar-Moncayo M; Ninomiya H; Ohno K; García-Moreno MI; Ortiz Mellet C; García Fernández JM; Suzuki Y
    Chembiochem; 2009 Nov; 10(17):2780-92. PubMed ID: 19830760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.